Danaher Corporation reported its first quarter 2025 financial results with adjusted earnings per share (EPS) of $1.88, surpassing the consensus estimate of $1.64. The company's revenue reached $5.74 billion, beating the expected $5.59 billion, despite a slight year-over-year decline of 0.95%. Danaher's non-GAAP free cash flow was $1.1 billion. The company attributed its outperformance to strong momentum in bioprocessing and unexpected demand in respiratory diagnostics. For the full year 2025, Danaher provided adjusted EPS guidance in the range of $7.60 to $7.75, close to the consensus midpoint of $7.67, and forecasted low-single-digit year-over-year core revenue growth for the second quarter. Meanwhile, Thermo Fisher Scientific also released its first quarter 2025 results, reporting adjusted EPS of $5.15, slightly above the previous $5.11 and the estimate of $5.11. Its revenue was $10.36 billion, exceeding the prior $10.23 billion and consensus expectations. Both companies demonstrated strong earnings performance in the life sciences and diagnostics sectors for the quarter.